Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1397-1406

  Deharvengt, Sophie ^a   Rejiba, Soukaina ^a   Wack, Séverine ^a   Aprahamian, Marc ^a   Hajri, Amor ^a  

^a IRCAD   (France)

Author keywords

E. coli purine nucleoside phosphorylase; Electrogene therapy; Electroporation; Pancreatic adenocarcinoma; Suicide gene therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLUDARABINE; MESSENGER RNA; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; VIDARABINE;

ADENOCARCINOMA; ANIMAL; ARTICLE; BACTERIAL GENE; DRUG SCREENING; ELECTROCHEMOTHERAPY; ELECTROPORATION; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; LEWIS RAT; METHODOLOGY; PANCREAS TUMOR; RAT; SUICIDE TRANSGENE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ELECTROCHEMOTHERAPY; ELECTROPORATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, BACTERIAL; GENES, TRANSGENIC, SUICIDE; HUMANS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PRODRUGS; PURINE-NUCLEOSIDE PHOSPHORYLASE; RATS; RATS, INBRED LEW; RNA, MESSENGER; VIDARABINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447258872     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1397     Document Type: Article

References (56)

1. Springer CJ and Niculescu-Duvaz I: Prodrug-activating systems in suicide gene therapy. J Clin Invest 105: 1161-1167, 2000.
2. Singhal S and Kaiser LR: Cancer chemotherapy using suicide genes. Surg Oncol Clin Am 7: 505-536, 1998. (Pubitemid 28354314)
3. Connors TA: The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2: 702-709, 1995.
4. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr and Parker WB: Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1: 233-238, 1994.
5. Deharvengt S, Wack S, Uhring M, Aprahamian M and Hajri A: Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2′-deoxyriboside. Pancreas 28: E54-E64, 2004.
6. Hughes BW, King SA, Allan PW, Parker WB and Sorscher EJ: Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem 273: 2322-2328, 1998.
7. Krohne TU, Shankara S, Geissler M, et al: Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34: 511-518, 2001.
8. Parker WB, Allan PW, Shaddix SC, et al: Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 55: 1673-1681, 1998.
9. Secrist JA III, Parker WB, Allan PW, et al: Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleos Nucleot 18: 745-757, 1999.
10. Ledley FD: Non-viral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 6: 1129-1144, 1995.
11. Mulligan RC: The basic science of gene therapy. Science 260: 926-932, 1993.
12. Crystal RG: Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404-410, 1995.
13. Weichselbaum RR and Kufe D: Gene therapy of cancer. Lancet 349: SII10-SII12, 1997.
14. Wolff JA, Malone RW, Williams P, et al: Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468, 1990. (Pubitemid 120007658)
15. Gehl J: Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 177: 437-447, 2003.
16. Muramatsu T, Nakamura A and Park HM: In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals. Int J Mol Med 1: 55-62, 1998.
17. Somiari S, Glasspool-Malone J, Drabick JJ, et al: Theory and in vivo application of electroporative gene delivery. Mol Ther 2: 178-187, 2000.
18. Tamura T, Nishi T, Goto T, et al: Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer. Hum Gene Ther 12: 1265-1276, 2001.
19. Li S, Zhang X and Xia X: Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electrogene therapy. J Natl Cancer Inst 94: 762-768, 2002.
20. Tamura T, Nishi T, Goto T, et al: Combination of IL-12 and IL-18 of electrogene therapy synergistically inhibits tumor growth. Anticancer Res 23: 1173-1179, 2003.
21. Heller L, Pottinger C, Jaroszeki MJ, Gilbert R and Heller R: In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanoma combined with electrochemotherapy induces long-term antitumor immunity. Melanoma Res 10: 577-583, 2000.
22. Li S, Zhang X, Xia S, Hanna E, et al: Intramuscular electroporation of INF-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 8: 400-407, 2001. (Pubitemid 32241940)
23. Mikata K, Uemura H, Ohuchi H, Ohta S, Nagashima Y and Kubota Y: Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation. Mol Cancer Ther 1: 247-252, 2002.
24. Cichon T, Jamrozy L, Glogowska J, Missol-Kolka E and Szala S: Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther 9: 771-777, 2002. (Pubitemid 34971308)
25. Goto T, Nishi T, Tamura T, et al: Highly efficient electrogene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 97: 354-359, 2000.
26. Goto T, Nishi T, Kobayashi O, et al: Combination electrogene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinoma in vivo. Mol Ther 10: 929-937, 2004.
27. Evrard S, Keller P, Hajri A, et al: Experimental pancreatic cancer in the rat treated by photodynamic therapy. Br J Surg 81: 1185-1189, 1994. (Pubitemid 24262952)
28. Pettengill OS, Faris RA, Bell RH Jr, Kuhlmann ET and Longnecker DS: Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am J Pathol 143: 292-303, 1993.
29. Mutter D, Hajri A, Tassetti V, Solis-Caxaj C, Aprahamian M and Marescaux J: Increased tumor growth and spread after laparoscopy vs. laparotomy: influence of tumor manipulation in a rat model. Surg Endosc 13: 365-370, 1999.
30. Parker WB, Allan PW, Hassan AE, Secrist JA III, Sorscher EJ and Waud WR: Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 10: 23-29, 2003.
31. Aghi Hochberg F and Breakefield XO: Prodrug activation enzymes in cancer gene therapy. J Gene Med 2: 148-164, 2000.
32. Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, Douglas JT and Curiel DT: Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 60: 6784-6787, 2000.
33. Wells DJ: Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 11: 1363-1369, 2004.
34. Lefesvre P, Attema J and van Bekkum D: A comparison of efficacy and toxicity between electroporation and adenoviral gene transfer. BMC Mol Biol 3: 12, 2002.
35. Molnar MJ, Gilbert R, Lu Y, et al: Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Mol Ther 10: 447-455, 2004.
36. Bigey P, Bureau MF and Scherman D: In vivo plasmid DNA electrotransfer. Curr Opin Biotechnol 13: 443-447, 2002.
37. Wolf H, Rols MP, Boldt E, Neumann E and Teissie J: Control by pulse parameters of electric field-mediated gene transfer in mammalian cells. Biophys J 66: 524-531, 1994. (Pubitemid 24058471)
38. Elez R, Piiper A, Kronenberger B, et al: Tumor regression by combination antisense therapy against Plk1 and bcl-2. Oncogene 22: 69-80, 2003.
39. Cemazar M, Sersa G, Wilson J, et al: Effective gene transfer to solid tumors using different non-viral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 9: 399-406, 2002.
40. Hong JS, Waud WR, Levasseur DN, et al: Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. Cancer Res 64: 6610-6615, 2004.
41. Durieux AC, Bonnefoy R, Bussot T and Freyssenet D: In vivo gene electrotransfer into skeletal muscle: effect of plasmid DNA on the occurrence and extent of muscle damage. J Gene Med 6: 809-816, 2004.
42. Heller LC and Coppola D: Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther 9: 1321-1325, 2002.
43. Lohr F, Lo DY, Zaharoff DA, et al: Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 61: 3281-3284, 2001.
44. Voeks D, Martiniello-Wilks R, Madden V, et al: Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 9: 759-768, 2002. (Pubitemid 34679303)
45. Mohr L, Shankara S, Yoon SK, et al: Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 31: 606-614, 2000.
46. Parker WB, King SA, Allan PW, et al: In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylases. Hum Gene Ther 8: 1637-1644, 1997.
47. Martiniello-Wilks R, Dane A, Voeks DJ, et al: Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 6: 43-54, 2004.
48. Gronevik E, von Steyem FV, Kalhovde JM, Tjelle TE and Mathiesen I: Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med 7: 218-227, 2005.
49. Lucas ML, Heller L, Coppola D and Heller R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5: 668-675, 2002.
50. Jain RK: Barriers to drug delivery in solid tumors. Sci Am 271: 58-65, 1994.
51. Peister A, Mellad JA, Wang M, Tucker HA and Prockop DJ: Stable transfection of MSCs by electroporation. Gene Ther 11: 224-228, 2004.
52. Wang Z, Troilo PJ, Wang X, et al: Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 11: 711-721, 2004.
53. Pierrefite-Carle V, Baque P, Gavelli A, et al: Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats. Gut 50: 387-391, 2002.
54. O'Malley BW, Cope KA, Chen SH, Li D, Schwarta MR and Woo SL: Combination gene therapy for oral cancer in a murine model. Cancer Res 56: 1737-1741, 1996. (Pubitemid 26118205)
55. Kishida T, Asada H, Sato E, et al: In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 8: 1234-1240, 2001.
56. Gothelf A, Mir LM and Gehl J: Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 29: 371-387, 2003.